- Benchmark sees a 22% upside for shares of Insulet (PODD) as analyst Jan Wald says an active third manufacturing line will likely alleviate tight OmniPod inventory.
- "We believe that greater customer retention, better market penetration as evidenced by new prescribers and improved margins from the new OmniPod insulin pump should drive upside in the shares," Wald adds.
- Shares initiated at Buy, price target is $44.
Benchmark starts Insulet at Buy
Oct 15 2013, 09:55 ET